Flagship Pioneering Merges Three Biotech Platforms Into Etcelera
Oct 29, 2026
Healthcare
CellCarta Adds Tempus to Companion Diagnostics Lab Network
Aug 6, 2026
CellCarta has added Tempus as the second commercial laboratory partner in its CDx Commercialization Lab Network to support oncology companion diagnostics in U.S. practice.
CellCarta has added Tempus as the second commercial laboratory partner in its CDx Commercialization Lab Network, the company announced in a press release.
The agreement adds Tempus to a network built to support oncology companion diagnostics for biopharma sponsors. CellCarta said it will develop and validate the companion diagnostic, generate analytical and clinical evidence, support regulatory submissions, and perform centralized immunohistochemistry and tissue testing.
Through Tempus Hub, healthcare providers can order tests, sample testing is routed to CellCarta, and results are sent back to ordering providers. Tempus joins Sonic Healthcare USA as the second member of the network.
CellCarta said the network is part of its CDx Accelerator Model, which covers four stages: Build, Validate, Launch, and Transfer. After approval, CellCarta activates commercial laboratory partners to support launch plans for centralized companion diagnostics.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Enterprise AI Brief, Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Enterprise
Nov 13 ETR survey: Claude leads enterprise AI tools on satisfaction and spending plans Nov 13 Peter Sarlin's PostScriptum takes majority stake in Finnish AI deployment firm Brillian Nov 13 Gondola says Codex lifted engineering output 25% as revenue more than doubled Nov 13 DuPont teams with Microsoft and NobleAI to speed up R&D with AI Nov 13 Korean AI startups fear Huang exit could delay planned NVIDIA investmentsMore from Life Sciences
Nov 13 Bracco and Avicenna.AI win FDA clearance for AI that flags brain aneurysms on CT scans Nov 13 Zus Health raises $33 million to build the data layer for healthcare AI Nov 13 Google DeepMind releases AlphaGenome 2 to predict DNA variant effects in specific cell types Nov 13 Taiwan hospital accelerator T+ MedIC names AI ECG and CT screening tools as first winners Nov 13 Sheinbaum meets OpenAI president Greg Brockman on AI in Mexican healthcareFree newsletter
Life AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
The Hackett Group
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
Taiwanese Health Technology Groups Test US Market in Dallas
Oct 14, 2026
Healthcare
AstraZeneca and Oracle Partner on AI for Clinical Trials
Oct 20, 2026
Healthcare
CMG Launches DataLab MCP Server for Equity Capital Markets Data
Oct 21, 2026
FinTech
Covera Health Names Two Executives to Support Imaging Expansion
Nov 02, 2026
Healthcare
Ultima Genomics to Sequence 80,000 Samples for UK Biobank Immune Study
Oct 19, 2026
Biotech
Free, six days a week
Daily AI Brief: the AI news that matters, in your inbox.